Cardiac angiotensin II receptors are upregulated by long-term inhibition of nitric oxide synthesis in rats

Circulation Research

Volumn 83, Issue 7, 1998, Pages 743-751

  Katoh, Makoto ^a   Egashira, Kensuke ^a   Usui, Makoto ^a   Ichiki, Toshihiro ^a   Tomita, Hideharu ^a   Shimokawa, Hiroaki ^a   Rakugi, Hiromi ^b   Takeshita, Akira ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Angiotensin II; Angiotensin receptor; Nitric oxide; Vascular remodeling

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN RECEPTOR; ARGININE; CANDESARTAN HEXETIL; HEART RECEPTOR; HYDRALAZINE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTICLE; CONTROLLED STUDY; HEART RATE; INFLAMMATION; MALE; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; RECEPTOR UPREGULATION; SYNTHESIS;

EID: 0032487326     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.83.7.743     Document Type: Article

References (52)

1. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med. 1993;329:2002-2012.
2. Griendling KK, Alexander RW. Endothelial control of the cardiovascular system: recent advances. FASEB J. 1996;10:283-292.
3. Garg UC, Hassid A. Nitric oxide generating vasodilators and 8-bromocyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat smooth muscle cells. J Clin Invest. 1989;83:1774-1777.
4. von der Leyen H, Gibbons GH, Morishita R, Lewis NP, Zhang L, Nakajima M, Kaneda Y, Cooke JP, Dzau VJ. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci U S A. 1995;92:1137-1141.
5. Cooke JP, Singer AH, Tsao P, Zera P, Rowan RA, Billingham ME. Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. J Clin Invest. 1992;90:1168-1172.
6. Niu XF, Smith CW, Kubes P. Intracellular oxidative stress induced by nitric oxide synthesis inhibition increases endothelial cell adhesion to neutrophils. Circ Res. 1994;74:1133-1140.
7. De Caterina R. Libby P, Peng HB, Thannickal VJ, Rajavashisth TB, Gimbrone MA Jr, Shin WS, Liao JK. Nitric oxide decreases cytokine-induced endothelial activation: nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest. 1995;96:60-68.
8. Peng HB, Libby P, Liao JK. Induction and stabilization of I kappa B alpha by nitric oxide mediates inhibition of NF-kappa B. J Biol Chem. 1995; 270:14214-14219.
9. Khan BV, Harrison DG, Olbrych MT, Alexander RW, Medford RM. Nitric oxide regulates vascular cell adhesion molecule 1 gene expression and redox-sensitive transcriptional events in human vascular endothelial cells. Proc Natl Acad Sci U S A. 1996;93:9114-9119.
10. Zeiher AM, Fisslthaler B, Schray-Utz B, Busse R. Nitric oxide modulates the expression of monocyte chemoattractant protein 1 in cultured human endothelial cells. Circ Res. 1995;76:980-986.
11. Egashira K, Inou T, Hirooka Y, Yamada A, Maruoka Y, Kai H, Sugimachi M, Suzuki S, Takeshita A. Impaired coronary blood flow response to acetylcholine in patients with coronary risk factors and proxymal atherosclerotic lesions. J Clin Invest. 1993;91:29-37.
12. Egashira K, Inou T, Hirooka Y, Kai H, Sugimachi M, Suzuki S, Kuga T, Urabe Y, Takeshita A. Effects of age on endothelium-dependent vasodilation of resistance coronary artery by acetylcholine in humans. Circulation. 1993;88:77-81.
13. Egashira K, Suzuki S, Hirooka Y, Kai H, Sugimachi M, Imaizumi T, Takeshita A. Impaired endothelium-dependent vasodilation of large epicardial and resistance coronary arteries in patients with essential hypertension: different responses to acetylcholine and substance P. Hypertension. 1995;25:201-206.
14. Zeiher AM, Drexler H, Saurbier B, Just H. Endothelium-mediated coronary blood flow modulation in humans: effects of age, atherosclerosis, hyperchlesterolemia, and hypertension. J Clin Invest. 1993;92:652-662.
15. Ito A, Egashira K, Kadokami T. Fukumoto Y, Takayanagi T. Nakaike R, Kuga T, Sueishi K, Shimokawa H, Takeshita A. Chronic inhibition of endothelium-derived nitric oxide synthesis causes coronary microvascular structural changes and hyperreactivity to serotonin in pigs. Circulation. 1995;92:2636-2644.
16. Numaguchi K, Egashira K, Takemoto M, Kadokami T. Shimokawa H, Sueishi K, Takeshita A. Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats. Hypertension. 1995;26:957-962.
17. Xu Y, Arnal JF, Hinglais N, Appay MD, Laboulandine I, Bariety J. Michel JP. Renal hypertension angiopathy: comparison between chronic NO suppression and DOCA-salt intoxication. Am J Hypertens. 1995;8:167-176.
18. G-nitro L-arginine methyl ester due to converting enzyme inhibition. J Cardiovasc Pharmacol. 1996;28:142-148.
19. Takemoto M, Egashira K, Usui M, Numagichi K, Tomita H, Tsutsui H, Shimokawa H, Sueishi K, Takeshita A. Important role of tissue angiotensin-convcrting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats. J Clin Invest. 1997;99:278-287.
20. Takemoto M, Egashira K, Tomita H, Usui M, Okamoto H, Kitabatake A, Shimokawa H, Sueishi K, Takeshita A. Chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade: effects on cardiovascular remodeling in rats induced by the long-term blockade of nitric oxide synthesis. Hypertension. 1997;30:1621-1627.
21. Kato H, Hou J, Chobanian AV, Brecher P. Effects of angiotensin II infusion and inhibition of nitric oxide synthase on the rat aorta. Hypertension. 1996;28:153-158.
22. Hernandez-Presa M, Bustos C, Ortego M, Tunon J, Renedo G, Ruiz-Ortega M. Egido J. Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kB activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation. 1997;95:1532-1541.
23. Shimada K, Yazaki Y. Binding sites for angiotensin II in human mononuclear leukocytes. J Biochem. 1978;84:1013-1015.
24. Scheidegger KJ, Butler S, Witztum JL. Angiotensin II increases macrophage-mediated modification of low density lipoprotein via a lipoxygenase-dependnet pathway. J Biol Chem. 1997;272:21609-21615.
25. Baker KM, Chemin MI, Wixson SK, Aceto JF. Renin-angiotensin system involvement in pressure-overload cardiac hypertrophy in rats. Am J Physiol. 1990;259:H324-H332.
26. Suzuki J, Matsubara H, Urakami M, Inada M. Rat angiotensin II (type IA) receptor mRNA regulation and subtype expression in myocardial growth and hypertrophy. Circ Res. 1993;73:439-447.
27. Meggs LG, Coupet J, Huang H, Cheng W, Li P, Capasso JM, Homcy CJ, Anversa P. Regulation of angiotensin II receptors on ventricular myocytes after myocardial infarction in rats. Circ Res. 1993;72:1149-1162.
28. Nio Y, Matsubara H, Murasawa S, Kanasaki M, Inada M. Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction. J Clin Invest. 1995;95:46-54.
29. Sun Y, Weber KT. Cells expressing angiotensin II receptors in fibrous tissue of rat heart. Cardiovasc Res. 1996;31:518-525.
30. Challah M, Nicoletti A, Arnal JF, Philippe M, Laboulandine I, Allegrini J, Alhenc-Gelas F, Danilov S, Michel JB. Cardiac angiotensin converting enzyme overproduction indicates interstitial activation in renovascular hypertension. Cardiovas Res. 1995;30:231-239.
31. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
32. Swedberg K, Held P, Kjekshus J, Rasmossen K, Ryden L, Wedel H. Results of the Cooperative New Scadinavian Enarapril Survival Study II (CONSENSUS II): Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. N Engl J Med. 1992;327:678-684.
33. Weber KT. Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation. Circulation. 1997;96:4065-4082.
34. Cahill PA, Redmond EM, Foster C, Sitzmann JV. Nitric oxide regulates angiotensin II receptors in vascular smooth muscle cells. Eur J Pharmacol. 1995;288:219-229.
35. Du Y, Yao A, Quo D, Inagami T, Wang DH. Differential regulation of angiotensin II receptor subtypes in rat kidney by low dietary sodium. Hypertension. 1995;25:872-877.
36. Tsuji T, Okada F, Yamaguchi K, Nakamura T. Molecular cloning of the large subunit of transforming growth factor type ß masking protein and expression of the mRNA in various rat tissues. Proc Natl Acid Sci U S A. 1990;87:8835-8839.
37. Komuro I, Katoh Y, Kaida T, Shibazaki Y, Kurabayashi M, Hoh E, Takaku F, Yazaki Y. Mechanical loading stimulates cell hypertrophy and specific gene expression in cultured rat cardiac myocytes: possible role of protein kinase C activation. J Biol Chem. 1991;266:1265-1268.
38. Rakugi H, Okamura A, Kamide K, Ohishi M, Sasamura H, Morishita R, Higaki J, Ogihara T. Recognition of tissue- and subtype-specific modulation of angiotensin II receptors using antibodies against AT1 and AT2 receptors. Hypertension Res. 1997;20:51-55.
39. Sechi LA, Griffin CA, Grady EF, Kalinyak JE, Schambelan M. Characterization of angiotensin II receptor subtypes in rat heart. Circ Res. 1992;71:1482-1489.
40. Villarreal FJ, Kim NN, Ungab GD, Printz MP, Dillmann WH. Identification of functional angiotensin II receptors on rat cardiac fibroblasts. Circulation. 1993;88:2849-2861.
41. Sun Y, Cleutjens JP, Diaz-Arias AA, Weber KT. Cardiac angiotensin converting enzyme and myocardial fibrosis in the rat. Cardiovasc Res. 1994;28:1423-1432.
42. Sappino AP, Schrch W, Gabbiani G. Differentiation repertoire of fibroblastic cell: expression of cytoskeletal proteins as marker of phenotypic modulations. Lab Invest. 1990;63:144-161.
43. Tomita H, Egashira K, Ohara Y, Takemoto M, Koyanagi M, Katoh M, Yamamoto H, Tamaki K, Shimokawa H, Takeshita A. Early induction of transforming growth factor-ß via angiotensin II type 1 receptors contributes to cardiac fibrosis induced by long-term blockade of nitric oxide synthesis in rats. Hypertension. 1998;32:273-279.
44. Schwartz K, Bastie D, Bouveret P, Oliviero P. Alonso S, Buckingham M. α-Skeletal muscle actin mRNA's accumulate in hypertrophied adult rat hearts. Circ Res. 1986;59:551-555.
45. Kim S, Ohta K, Hamaguchi A, Yukimura T, Miura K, Iwao H. Angiotensin II induces cardiac phenotypic modulation and remodeling in vivo in rats. Hypertension. 1995;25:1252-1259.
46. Nakajima M, Hutchinson HG, Fujinaga M, Hayashida W, Morishita R, Zhang L, Horiuchi M, Pratt RE, Dzau VJ. Angiotensin II type 2 (AT2) receptor antaginizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer. Proc Natl Acad Sci U S A. 1995;92: 10663-10667.
47. Ichiki T, Usui M, Katoh M, Takeshita A. Downregulation of angiotensin II type 1 receptor by nitric oxide. Hypertension. 1998;31:342-348.
48. Murphy TJ, Alexander AW, Griendling KK, Runge MS, Bernstein KE. Isolation of a cDNA encoding the vascular type-1 angiotensin receptor. Nature. 1991;351:233-236.
49. Sasaki K, Yamano Y, Bardhan S, Iwai N, Murray JJ, Hasegawa M, Matsuda Y, Inagami T. Cloning and expression of a complementary DNA encoding a bovine adrenal angiotensin II type-1 receptor. Nature. 1991; 351:230-233.
50. Haller H, Behrend M, Park JK, Schaberg T, Luft FC, Distler A. Monocyte infiltration and c-fms expression in hearts of spontaneously hypertensive rats. Hypertension. 1995;25:132-138.
51. Hinglais N, Heudes D, Nicoletti A, Mandet C, Laurent M, Bariety J. Michel JB. Colocalization of myocardial fibrosis and inflammatory cells in rats. Lab Invest. 1994;70:286-294.
52. Nicoletti A, Heudes D, Mandet C, Hinglais N, Bariety J, Michel JB. Inflammatory cells and myocardial fibrosis: spatial and temporal distribution in renovascular hypertensive rats. Cardiovasc Res. 1996;32: 1096-1107.